# SOLARA (NCT06706076)

> A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06706076
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: BlossomHill Therapeutics
- Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions: BH-30643; BH-30643 combo therapy with Carboplatin/Pemetrexed; BH-30643
- Enrollment: 675
- Primary outcome: Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation)
- Primary outcome: Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization)
- Primary outcome: Objective Response Rate (ORR) (Phase 2)

## Commentary we found

- X threads: 9

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=solara-nct06706076

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06706076", "email": "<work email>"}; the inbox owner confirms by the emailed link.